TriangleNCT01771107 · OUTCOME
CD4 Counts
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- cells/µL
- Interval / dispersion
- Inter-Quartile Range
- Time frame
- 5 months
What was measured
CD4 counts (absolute) at visit 4 (cycle 5)
Analysis population: Participants with absolute cd4 counts at cycle 5
Groups in this outcome
Phase I - Brentuximab 1.2 mg/kg
Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV
Phase II - Brentuximab 1.2 mg/kg
Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV
| Group | Source count |
|---|---|
| Phase I - Brentuximab 1.2 mg/kg | 6 |
| Phase II - Brentuximab 1.2 mg/kg | 26 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Phase I - Brentuximab 1.2 mg/kg | 378 | Not reported | 289 | 530 | Not reported |
| Phase II - Brentuximab 1.2 mg/kg | 401 | Not reported | 292 | 481 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 289
- upper Limit
- 530
- value
- 378
- group Id
- OG001
- lower Limit
- 292
- upper Limit
- 481
- value
- 401
- denoms
- counts
- group Id
- OG000
- value
- 6
- group Id
- OG001
- value
- 26
- units
- Participants
- description
- CD4 counts (absolute) at visit 4 (cycle 5)
- dispersion Type
- Inter-Quartile Range
- groups
- description
- Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV
- id
- OG000
- title
- Phase I - Brentuximab 1.2 mg/kg
- description
- Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Brentuximab Vedotin: Given IV Dacarbazine: Given IV Doxorubicin Hydrochloride: Given IV Pharmacological Study: Correlative studies Vinblastine: Given IV
- id
- OG001
- title
- Phase II - Brentuximab 1.2 mg/kg
- param Type
- MEDIAN
- population Description
- Participants with absolute cd4 counts at cycle 5
- reporting Status
- POSTED
- time Frame
- 5 months
- title
- CD4 Counts
- type
- SECONDARY
- unit Of Measure
- cells/µL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice